Acute and chronic systemic corticosteroid-related complications in patients with severe asthma

被引:174
作者
Lefebvre, Patrick [1 ]
Duh, Mei Sheng [2 ]
Lafeuille, Marie-Helene [1 ]
Gozalo, Laurence [1 ]
Desai, Urvi [2 ]
Robitaille, Marie-Noelle [1 ]
Albers, Frank [3 ]
Yancey, Steve [3 ]
Ortega, Hector [3 ]
Forshag, Mark [3 ]
Lin, Xiwu [3 ]
Dalal, Anand A. [3 ]
机构
[1] Ltee, Grp Anal, Montreal, PQ H3B 4W5, Canada
[2] Anal Grp, Boston, MA USA
[3] GlaxoSmithKline, Durham, NC USA
关键词
Systemic corticosteroids; severe asthma; health care use; dose response; corticosteroid-related complications; cost; ORAL CORTICOSTEROIDS; LUPUS-ERYTHEMATOSUS; GLUCOCORTICOID USE; REFRACTORY ASTHMA; ADVERSE EVENTS; RISK; DISEASE; MULTICENTER; FRACTURE; REGISTRY;
D O I
10.1016/j.jaci.2015.07.046
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: Many patients with severe asthma require maintenance treatment with systemic corticosteroids (SCSs) to control daily symptoms and prevent serious acute exacerbations, but chronic SCS use is associated with complications. Objective: We sought to evaluate the risk of SCS-related complications by SCS exposure and quantify the associated health care costs and resource use in patients with severe asthma. Methods: We performed a longitudinal, open-cohort, observational study using health insurance claims data (1997-2013: Medicaid) from Florida, Iowa, Kansas, Missouri, Mississippi, and New Jersey. Eligible patients were 12 years old or older with 2 or more asthma diagnoses and had more than 6 months of continuous SCS use. An open-cohort approach was used to classify patients' follow-up into low, medium, and high SCS exposure (<= 6, >6-12, and >12 mg/d, respectively). Multivariate generalized estimating equation models were used to estimate the adjusted risk of SCS-related complications for patients with medium and high exposure compared with patients with low exposure and quantify the resulting health care resource use and costs. Results: The study included 3628 patients (mean age, 57.6 years; 68% female). Patients with medium and high SCS exposure had significantly higher risks of SCS-related complications, including infections and cardiovascular, metabolic, psychiatric, ocular, gastrointestinal, and bone-related complications (odds ratio, 1.23-2.12 by complication; P<.05 for all but one) versus those with low (reference group) SCS exposure. Medium and high SCS exposure were also associated with significantly more emergency department visits (incidence rate ratios, 1.31 [P=.0004] and 1.78 [P<.0001]) and inpatient visits (incidence rate ratios, 1.25 [P<.0001] and 1.59 [P<.0001]) versus low SCS exposure. Conclusions: A significant dose-response relationship was demonstrated between chronic SCS use and risk of SCS-related complications in patients with severe asthma. Effective SCS-sparing strategies might reduce the burden associated with SCS-related complications in patients with severe asthma.
引用
收藏
页码:1488 / 1495
页数:8
相关论文
共 29 条
[1]   The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma [J].
Abraham, B ;
Antó, JM ;
Barreiro, E ;
Bel, EHD ;
Bonsignore, G ;
Bousquet, J ;
Castellsague, J ;
Chanez, P ;
Cibella, F ;
Cuttitta, G ;
Dahlén, B ;
Dahlén, SE ;
Drews, N ;
Djukanovic, R ;
Fabbri, LM ;
Folkerts, G ;
Gaga, M ;
Gratziou, C ;
Guerrera, G ;
Holgate, ST ;
Howarth, PH ;
Johnston, SL ;
Kanniess, F ;
Kips, JC ;
Kerstjens, HAM ;
Kumlin, M ;
Magnussen, H ;
Nijkamp, FP ;
Papageorgiou, N ;
Papi, A ;
Postma, DS ;
Pauwels, RA ;
Rabe, KF ;
Richter, K ;
Roldaan, AC ;
Romagnoli, M ;
Roquet, A ;
Sanjuas, C ;
Siafakas, NM ;
Timens, W ;
Tzanakis, N ;
Vachier, I ;
Vignola, AM ;
Watson, L ;
Yourgioti, G .
EUROPEAN RESPIRATORY JOURNAL, 2003, 22 (03) :470-477
[2]  
[Anonymous], 2014, CONS PRIC IND CPI
[3]  
[Anonymous], 2007, GUID DIAGN MAN ASTHM
[4]   Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma [J].
Bel, Elisabeth H. ;
Wenzel, Sally E. ;
Thompson, Philip J. ;
Prazma, Charlene M. ;
Keene, Oliver N. ;
Yancey, Steven W. ;
Ortega, Hector G. ;
Pavord, Ian D. .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (13) :1189-1197
[5]   A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION [J].
CHARLSON, ME ;
POMPEI, P ;
ALES, KL ;
MACKENZIE, CR .
JOURNAL OF CHRONIC DISEASES, 1987, 40 (05) :373-383
[6]   Population-based assessment of adverse events associated with long-term glucocorticoid use [J].
Curtis, Jeffrey R. ;
Westfall, Andrew O. ;
Allison, Jeroan ;
Bijlsma, Johannes W. ;
Freeman, Allison ;
George, Varghese ;
Kovac, Stacey H. ;
Spettell, Claire M. ;
Saag, Kenneth G. .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2006, 55 (03) :420-426
[7]   Safety of low dose glucocorticoid treatment in rheumatoid arthritis:: published evidence and prospective trial data [J].
Da Silva, JAP ;
Jacobs, JWG ;
Kirwan, JR ;
Boers, M ;
Saag, KG ;
Inês, LBS ;
de Koning, EJP ;
Buttgereit, F ;
Cutolo, M ;
Capell, H ;
Rau, R ;
Bijlsma, JWJ .
ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (03) :285-293
[8]   Fracture risk with intermittent high-dose oral glucocorticoid therapy [J].
de Vries, Frank ;
Bracke, Madelon ;
Leufkens, Hubert G. A. ;
Lammers, Jan-Willem J. ;
Cooper, Cyrus ;
van Staa, Tjeerd P. .
ARTHRITIS AND RHEUMATISM, 2007, 56 (01) :208-214
[9]  
Global Initiative for Asthma, 2014, GLOB STRAT ASTHM MAN
[10]   Refractory asthma in the UK: cross-sectional findings from a UK multicentre registry [J].
Heaney, Liam G. ;
Brightling, Chris E. ;
Menzies-Gow, Andrew ;
Stevenson, Michael ;
Niven, Rob M. .
THORAX, 2010, 65 (09) :787-794